PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31
PROTHENA CORP PUBLIC LTD CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.48+0.13 (+1.56%)
Close on Oct 19, 2026
- Market cap
- $442.19M
- P/E (TTM)
- –
- Dividend yield
- –
PROTHENA CORP PUBLIC LTD CO revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $9.63M | $135.11M | $91.32M | $13.86M | $139.83M | $564.00K | $814.00K | $1.00M | – | – | 99.5% | -92.9% |
| Revenue from license and intellectual property | $50.00K | $50.00K | $50.00K | $40.05M | $60.74M | $289.00K | $0 | $0 | – | – | 0.5% | 0.0% |
By region
From the segment and revenue-disaggregation notes of Prothena Corp Public's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.